youtube_live
Q3 2026 earnings • released • EPS beat +19.31% • Revenue beat +3.96%
See resultschevron_right
TEVA:NYSE
Teva Pharmaceutical Industries Limited
$41.78
arrow_downward
-0.17%(-0.070) 1D
$41.80
arrow_upward
+0.05% (+0.020)bedtimeAfter hours
Closed: Nov 5, 4:00:03 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TEVA...
Open
$41.49
High
$42.38
Low
$40.92
Mkt. cap
47.90B
Avg. vol.
6.57M
Volume
0.00
52-wk high
$43.34
52-wk low
$23.61
Beta
1.15
Shares outstanding
1.17B
No. of employees
32K
Open
$41.49
High
$42.38
Low
$40.92
Mkt. cap
47.90B
Avg. vol.
6.57M
Volume
0.00
52-wk high
$43.34
52-wk low
$23.61
Beta
1.15
Shares outstanding
1.17B
No. of employees
32K
News stories
From web sources and news partners
GuruFocus
·
6 hours ago
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call
TradingView
·
1 day ago
Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
Investing.com
·
1 day ago
MindWalk secures multi-year AI deal with Teva Australia
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States.
Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America.
Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEORichard Francis
Employees32K
FoundedFeb 13, 1944
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteteva.co.il
Analyst ratings
Based on 9 analysts giving stock ratings to TEVA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TEVA in the last 3 months.
Highest
Current $41.78
$50.00 (+19.67%)
Average
$44.00 (+5.31%)
Lowest
$40.00 (-4.26%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Daniel Clark Leerink Partners | Buy | Initiated | $45.00 | +7.7% | 09/09/2026 |
Ashwani Verma UBS | Buy | Maintained | $48.00 | +14.9% | 09/04/2026 |
Dennis Ding Jefferies | Buy | Maintained | $40.00 | -4.3% | 09/03/2026 |
Louise Chen Scotiabank | Buy | Maintained | $40.00 | -4.3% | 09/03/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $50.00 | +19.7% | 09/02/2026 |
Jason Gerberry Bank of America Securities | Buy | Reiterated | $43.00 | +2.9% | 09/02/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 09/02/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $44.00 | +5.3% | 08/27/2026 |
Glen Santangelo Barclays | Buy | Maintained | $42.00 | +0.5% | 08/12/2026 |
Chris Schott J.P. Morgan | Buy | Maintained | - | - | 06/15/2026 |
Matthew Dellatorre Goldman Sachs | Buy | Maintained | $50.00 | +19.7% | 04/30/2026 |
Les Sulewski Truist Financial | Buy | Reiterated | $45.00 | +7.7% | 04/30/2026 |
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.86 / $0.72
+19.31%beat
arrow_upward
Revenue / Est. (USD)
4.40B / 4.23B
+3.96%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 4.71B | 3.98B | 4.14B | 4.40B |
Cost of goods sold | 2.06B | 2.01B | 1.99B | 1.96B |
Cost of revenue | 2.06B | 2.01B | 1.99B | 1.96B |
Research and development expenses | 267.00M | 222.00M | 970.00M | 297.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.12B | 1.00B | 1.03B | 1.01B |
Operating expense | 1.37B | 1.21B | 1.99B | 1.24B |
Total operating expenses | 3.43B | 3.22B | 3.98B | 3.19B |
Operating income | 1.28B | 763.00M | 167.00M | 1.20B |
Other non operating income | - | -13.00M | -69.00M | -22.00M |
EBT including unusual items | 90.00M | 436.00M | -455.00M | 300.00M |
EBT excluding unusual items | 1.08B | 547.00M | -57.00M | 1.01B |
Income tax expense | -390.00M | 67.00M | 121.00M | 66.00M |
Effective tax rate | -433.33% | 15.37% | -26.59% | 22.00% |
Other operating expenses | -17.00M | -14.00M | -18.00M | -68.00M |
Net income | 480.00M | 369.00M | -576.00M | 233.00M |
Net profit margin | 10.19% | 9.27% | -13.91% | 5.30% |
Earnings per share | 0.96 | 0.53 | 0.02 | 0.86 |
Interest and investment income | 92.00M | - | - | - |
Interest expense | -280.00M | -191.00M | -186.00M | -138.00M |
Net interest expenses | -188.00M | -191.00M | -186.00M | -138.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.54B | 1.00B | 408.00M | 1.45B |
Gain or loss from assets sale | - | -8.00M | -12.00M | -69.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events